Methylnaltrexone: The answer to opioid-induced constipation?

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 6, 2009, Pages 1039-1045

  Cannom, Rebecca R ^a   Mason, Rodney J ^a  

^a NONE   (United States)

Author keywords

Alvimopan; Constipation; Gastroparesis; Methylnaltrexone; Opioid receptor antagonist; Opioids; Oral cecal transit time; Quaternary amine

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; LAXATIVE; METHADONE; MORPHINE; NALMEFENE; NALOXONE; NALTREXONE; OPIATE; OPIATE RECEPTOR; RELISTOR; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANALGESIA; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; CANCER PAIN; CANCER PATIENT; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; FOOD AND DRUG ADMINISTRATION; HUMAN; IC 50; INTESTINAL DYSMOTILITY; NAUSEA; ORTHOSTATIC HYPOTENSION; POSTOPERATIVE PAIN; RECEPTOR BLOCKING; REVIEW; SINGLE DRUG DOSE; SURGICAL PATIENT; TERMINALLY ILL PATIENT; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; ANIMALS; CONSTIPATION; GASTROINTESTINAL TRANSIT; HUMANS; NALTREXONE; QUATERNARY AMMONIUM COMPOUNDS;

EID: 67649622275     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902833914     Document Type: Review

References (26)

1. Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother 2007;41(6):984-993 (Pubitemid 46917625)
2. Fallon MT, Hanks GW. Morphine, constipation and performance status in advanced cancer patients. Palliat Med 1999;13(2):159-160
3. Van Orden H. Constipation: an overview of treatment. J Pediatr Health Care 2004;18(6):320-322 (Pubitemid 39452290)
4. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 2000;283(3):367-372 (Pubitemid 30051755)
5. Brown DR, Goldberg LI. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 1985;24(3):181-191 (Pubitemid 15051584)
6. DeFrances CJ, Hall MJ. 2005 National hospital discharge survey. Adv Data Vital Health Stat 2005;385:1-20
7. Schug SA, Zech P, Grond S, et al. A long-term survey of morphine in cancer pain patients. J Pain Symptom Manage 1992;7(5):259-266
8. Sykes NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 1998;12(5):375-382 (Pubitemid 28454405)
9. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182(5A Suppl):11S-18S (Pubitemid 34072942)
10. Sykes NP. Oral naloxone in opioid-associated constipation. Lancet 1991;337(8755):1475
11. ENTEREG (alvimopan) Capsules Prescribing Information. 2008, GlaxoSmithKline: Triangle Park, NC
12. Relistor package insert., Wyeth Pharmaceuticals: Philadelphia, PA
13. Manara L, Bianchetti A. The central and peripheral influences of opioids on gastrointestinal propulsion. Annu Rev Pharmacol Toxicol 1985;25:249-273 (Pubitemid 15090982)
14. Kraft MD. Methylnaltrexone, a new peripherally acting mu-opioid receptor antagonist being evaluated for the treatment of postoperative ileus. Expert Opin Investig Drugs 2008;17(9):1365-1377
15. Yuan CS, Doshan H, Charney MR, et al. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol 2005;45(5):538-546 (Pubitemid 40562944)
16. Foss JF, O'Connor MF, Yuan CS, et al. Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. J Clin Pharmacol 1997;37(1):25-30 (Pubitemid 27131551)
17. Yuan CS, et al. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 1996;59(4):469-475 (Pubitemid 26151630)
18. Yuan CS, Foss JF, Moss J. Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine. Eur J Pharmacol 1995;276(1-2):107-111
19. Murphy DB, Sutton JA, Prescott LF, et al. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology 1997;87(4):765-770 (Pubitemid 27456227)
20. Yuan CS, Wei G, Foss JF, et al. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther 2002;300(1):118-123 (Pubitemid 34028517)
21. Yuan CS, Foss JF, Osinski J, et al. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther 1997;61(4):467-475 (Pubitemid 27195949)
22. Yuan CS, Foss JF. Oral methylnaltrexone for opioid-induced constipation. JAMA 2000;284(11):1383-1384
23. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358(22):2332-2343 (Pubitemid 351749157)
24. Lang L. The food and drug administration approves methylnaltrexone bromide for opioid-induced constipation. Gastroenterology 2008;135(1):6 (Pubitemid 351899040)
25. McNicol ED, Boyce D, Schumann R, et al. Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev 2008;(2):CD006332 (Pubitemid 351807375)
26. Woo M, O'connor M, Yuan CS, et al. Reversal of opioid-induced gastric dysfunction in a critically ill burn patient after methylnaltrexone. Anesth Analg 2008;107(6):1965-1967